Guidance and Support Booklet for Your Patients Prescribed Xalkori®

This booklet is designed to be distributed by Healthcare Professionals  to patients who have been prescribed Xalkori®. The booklet offers general advice on ALK-positive and ROS1-positive NCSLC and specific information about treatment with Xalkori®.


Click here to download the XALKORI® Patient Information Booklet



1. Pfizer. Xalkori® (crizotinib) Summary of Product Characteristics


Legal Category: S1A

PP-XLK-IRL-0198 Date of preparation: April 2021